Sort   by:  
 Page size 
ProteomicsTargeting non-canonical NF-κB signalling in CYLD cutaneous syndrome by selective inhibition of IκB kinase alpha
Proteome of CD45- sorted healthy skin (C1-C5) and CD45-/CD200+ CYLD cutaneous syndrome tumour samples (T1-T5).
ORGANISM(S): Homo sapiens (Human) 
2026-05-13 | PXD053466 | Pride
Cyld Skin Human Nf-kb 
UnknownRed-flag sepsis and SOFA identifies different patient population at risk of sepsis-related deaths on the general ward.
Not available
S-EPMC6310498 | biostudies-literature
UnknownSepsis-related deaths in the at-risk population on the wards: attributable fraction of mortality in a large point-prevalence study.
Not available
S-EPMC6182791 | biostudies-literature
UnknownFour consecutive yearly point-prevalence studies in Wales indicate lack of improvement in sepsis care on the wards.
Not available
S-EPMC8355110 | biostudies-literature
UnknownEmpagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC10957483 | biostudies-literature
UnknownHigher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC11872607 | biostudies-literature
UnknownAzithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC7884931 | biostudies-literature
UnknownEffect of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Not available
S-EPMC7556338 | biostudies-literature
UnknownDexamethasone in Hospitalized Patients with Covid-19.
Not available
S-EPMC7383595 | biostudies-literature
UnknownCasirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8830904 | biostudies-literature
Sort   by:  
 Page size